Chemotherapy options in castration-resistant prostate cancer.

ABSTRACT:

Introduction

The treatment landscape for patients with metastatic castration-resistant prostate cancer (CRPC) is evolving, with recent approvals of immune therapy, novel hormonal therapy, and bone-targeted therapy. Chemotherapy remains an essential component of the armamentarium. Herein, we review current chemotherapy options for patients with CRPC and discuss future challenges.

Methods

We reviewed literature for chemotherapy agents in prostate cancer, with special attention to the evidence for efficacy of the currently approved agents. We also reviewed emerging data on biomarkers of response to chemotherapy for CRPC.

Results

Taxanes, especially docetaxel and cabazitaxel, have first- and second-line indications for CRPC, respectively, with both providing a survival be

SUBMITTER: Teply BA 

PROVIDER: S-EPMC5054655 | biostudies-literature | 2016 Oct-Dec

REPOSITORIES: biostudies-literature